Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540621 | 0.78 | — | — | |
| SCHEMBL3540618 | 0.78 | — | — | |
| SCHEMBL12349050 | 0.77 | — | — | |
| SCHEMBL4288374 | 0.76 | — | — | |
| SCHEMBL1551862 | 0.61 | SHBG (0.31) | — | |
| SCHEMBL1551888 | 0.61 | SHBG (0.35) | SLC6A4 | |
| SCHEMBL10576267 | 0.60 | TSHR (0.41) | — | |
| SCHEMBL149054 | 0.60 | TSHR (0.41) | — | |
| SCHEMBL1550898 | 0.59 | SHBG (0.38) | — | |
| SCHEMBL1550895 | 0.59 | SHBG (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313374-B1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| EP-2313374-B1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-05-02 | — | — | US | disclosed |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-05-02 | — | — | US | disclosed |
| US-8399482-B2 | 6-substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-8399482-B2 | 6-substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-2313374-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | Sanofi-Aventis (FR) | 2011-04-27 | — | — | EP | disclosed |
| WO-2009156099-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156099-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | MYLK2, MYLK, MYLK3 | SLC6A4 3016/4885 |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | MYLK2, MYLK, MYLK3 | SLC6A4 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.